Ultrasonic Aspirator Guidance Requires Warning On Uterine Use
Executive Summary
Manufacturers of 510(k)-cleared ultrasonic aspirators have 120 days to add labeling to the products that warns against use to remove uterine fibroids.
You may also be interested in...
US FDA: Ultrasonic Tools Shouldn't Be Used For Uterine Surgery
Draft guidance issued Nov. 10 recommends manufacturers of surgical aspiration devices add a contraindication to their product labeling stating the tools are not for use in uterine surgery. This is due to a perceived risk of spreading cancerous tissue, which also led to a similar warning on power morcellation devices in 2014.
FDA Puts Black Box Warning On Power Morcellators With Immediately-In-Effect Guidance
FDA has followed through on the advice of its advisory panel by requiring new labeling for power morcellators used to treat uterine fibroids, emphasizing the procedure’s potential to spread cancer. FDA wants to restrict the power morcellation procedure to younger women who are interested in maintaining their ability to have children and who have been thoroughly informed of the risks.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.